Acetyl-PARP1 (K521) Antibody

1. elevated expression of PARP-1 mRNA and miR-223, with a reduction of PARP-1 protein level and enzyme activity in colonic tissue of pediatric patients with Crohn's disease PMID: 30299179
2. miR-7-5p reduced energy consumption via inhibiting PARP-1 expression, and miR-7-5p increased energy generation by suppressing the expression of Bcl-2. PMID: 30219819
3. Study finds that PARP1 mutations caused a distinct set of drug sensitivities when compared to other known forms of PARPi resistance (loss of REV7 (MAD2L2) or TP53BP1, or BRCA1 reversion mutants), suggesting that knowledge of the molecular mechanism of resistance in individual patients could inform decisions on further treatment. PMID: 29748565
4. Results suggest that RNF168 acts as a counterpart of PARP1 in DDR and regulates the HR/NHEJ repair processes through the ubiquitination of PARP1. PMID: 30037213
5. two-step mechanism activates and then stabilizes PARP-1 on a DNA break, indicating that PARP-1 allostery influences persistence on DNA damage, with important implications for PARP inhibitors that engage the NAD(+) binding site PMID: 29487285
6. PARP-1, via manipulating the binding of NF-kB/AP-1 at the MMP-9 promoter, regulates MMP-9 expression, which helps maintain mitochondrial homeostasis. PMID: 28478229
7. Cell proliferation determines PARP1 transcription and production of electrophiles. PARP1 contributes to cell protection against electrophiles. PARP1 controls transcription of redox-sensitive kinases, antioxidants and detoxifying enzymes. [review] PMID: 29886395
8. interactive domains between Ets-1 and PARP-1 have been mapped to the C-terminal region of Ets-1 and the BRCA1 carboxy-terminal (BRCT) domain of PARP-1 PMID: 29912634
9. depletion of NOX1 and NOX4 partially rescued the growth inhibition of PARP1-deficient tumor xenografts. Our findings suggest that in addition to compromising the repair of DNA damage, PARP inhibition or depletion may exert extra antitumor effect by elevating oxidative stress in ovarian cancer cells PMID: 29684820
10. CDK4/6 inhibitors also lead to accumulation of DNA damage by repressing PARP1 in oxidatively stressed cells. Thus, CDK4/6 inhibitors sensitize G1-arrested cells to anticancer drugs, since these cells require PARP1-OGG1 functional interaction for cell survival PMID: 29306194
11. Low PARP expression is associated with mouth Cancer. PMID: 30275188
12. The dysfunction of PARP1 in esophageal epithelial cells increases the levels of ROS and oxidative DNA damage in Barrett's esophagus. PMID: 29531462
13. results suggest that PARP-1 overexpression may define an important risk factor in non-M3 AML patients and PARP-1 is a potential therapeutic target for AML treatment PMID: 29812960
14. polymorphism of PARP-1 gene is more likely responsible for development of GD in Chinese individuals PMID: 28177666
15. In response to DNA damage, activated and auto-poly-ADP-ribosylated PARP1 dissociates from HSF1-PARP13, and redistributes to DNA lesions and DNA damage-inducible gene loci. PMID: 29158484
16. Results show that Rpp29 and Rpp21 bind poly ADP-ribose moieties and are recruited to DNA damage sites in a PARP1-dependent manner. PMID: 28432356
17. PARP1 inhibitor also suppressed the aldosterone secretion in response to the angiotensin II. Together, these results suggest PARP1 is a prime coregulator for Nurr1. PMID: 29738496
18. Here, we show that PARP1 and host insulator protein CTCF colocalize at specific sites throughout the EBV genome and provide evidence to suggest that PARP1 acts to stabilize CTCF binding and maintain the open chromatin landscape at the active Cp promoter during type III latency. Further, PARP1 activity is important in maintaining latency type-specific viral gene expression. PMID: 29976663
19. Our findings showed that PARP-1 polymorphisms are involved in the development of glioma in Chinese individuals. PMID: 28777431
20. Our results indicated that PARP1-siRNA can suppress the growth and invasion capacity of prostate cancer cells, thereby suggesting that PARP1-siRNA, which is different from PARP inhibitors , may provide a potential treatment method for prostate cancer . PMID: 29393407
21. findings reveal PARP-1 as a double-edged sword in colorectal carcinogenesis, which suppresses tumor initiation following DNA alkylation in a MGMT-dependent manner, but promotes inflammation-driven tumor progression. PMID: 29632181
22. data indicate that RNF20 and PARP1 are synthetic lethal interactors PMID: 28462496
23. High PARP1 expression is associated with colonic neoplasms. PMID: 29590171
24. On DNA damage, CIRBP temporarily accumulates at the damaged regions and is poly(ADP ribosyl)ated by poly(ADP ribose) polymerase-1 (PARP-1). PMID: 29432179
25. The study suggests that PARP-1 polymorphisms are involved in the development of SCI in Chinese individuals. Thus, PARP-1 polymorphisms can be considered as one of the potential risk factors for developing SCI. PMID: 29255350
26. this study identifies the importance of TDP1 as a novel determinant of response to CNDAC across various cancer types (especially non-small cell lung cancers), and demonstrates the differential involvement of BRCA2, PARP1, and TDP1 in the cellular responses to CNDAC, AraC, and CPT PMID: 28802254
27. Variations in potential miRNA-binding target sites in the 3' UTR of PARP1 gene may modulate colorectal cancer risk and prognosis after therapy. PMID: 29048575
28. Three-locus model of gene-gene interactions OGG1 (rs1052133) * ADPRT (rs1136410) * XRCC4 (rs6869366) was associated with high genotoxic risk in coal miners. PMID: 28992182
29. Observations suggest that IER5 is a novel regulator of the non-homologous end-joining pathway pathway for DNA double-strand breaks repair, possibly through its interaction with PARP1 and Ku70. PMID: 29104487
30. This study identified the involvement of two SNPs of PARP-1 (C410T and G1672A) in development of acute renal injury among Chinese diabetic patients. PMID: 29238179
31. Studies indicate that post-translational modifications (PTMs) such as phosphorylation, acetylation, and methylation are crucial for the regulation of PARP1 activity, and dysregulation of modifications on PARP1 is observed in cancer [Review]. PMID: 28930534
32. Poly(ADP-ribose) polymerase-1 (PARP1) interacts with xeroderma pigmentosum, complementation group C protein (XPC) in the nucleoplasmic and chromatin fractions in UV irradiated HEK293 cells. PMID: 28760956
33. The phosphorylation level of p38 was upregulated by MA1 treatment, and the inhibitor of p38, SB203580, attenuated the MA1-induced p38 phosphorylation as well as caspase3 and PARP activation. These results indicate that MA1 treatment alters invasive and oncogenic phenotypes of human colorectal cancer cells through the stimulation of the p38 signaling pathway PMID: 28713983
34. this study demonstrates that PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway PMID: 28457938
35. Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. PMID: 27484730
36. NR1D1 interacted with poly(ADP-ribose) polymerase 1 (PARP1) and subsequently inhibited catalytic activity of PARP1. PMID: 28599788
37. IGH/MYC-positive Burkitt lymphoma/leukemia cells have decreased BRCA2 and are sensitive to PARP1 inhibition alone or in combination with other chemotherapies. This study postulates that IGH/MYC-induced BRCA2 deficiency may predispose Burkitt lymphoma cells to synthetic lethality triggered by PARP1 inhibitors. PMID: 28634224
38. Our study demonstrates a cross-talk between PARPi and tumor-associated immunosuppression and provides evidence to support the combination of PARPi and PD-L1 or PD-1 immune checkpoint blockade as a potential therapeutic approach to treat breast cancer PMID: 28167507
39. PARP1 expression was increased in GBM at both mRNA and protein levels. increased PARP1 levels show positive correlation with increasing tumour grades in gliomas Higher PARP1 mRNA expression levels were associated with ATRX and TP53 mutations. PMID: 28654422
40. Existence of a kinase-independent role of nuclear RIPK1 in the regulation of PARP1. PMID: 28993228
41. The observed incomplete sister chromatid disjunction may be due to the accumulation of unreplicated DNA during mitosis in CDA-deficient cells, as reflected in the changes in centromeric DNA structure associated with the decrease in basal PARP-1 activity. PMID: 28463527
42. Studied role of PARP1 regulation and senescence by melatonin. PMID: 28247536
43. Report a requirement for PARP2 in stabilizing replication forks that encounter base excision repair (BER) intermediates through Fbh1-dependent regulation of Rad51. Whereas PARP2 is dispensable for tolerance of cells to single stranded breaks or homologous recombination dysfunction, it is redundant with PARP1 in BER. PMID: 29467415
44. Potential high binding affinity compounds that are predicted by molecular simulations were then tested by in vitro methods. Computationally proposed compounds as PARP-1 inhibitors were confirmed by in vitro studies. In vitro results showed that compounds 7111620047 and 7119980926 have IC50 values of 0.56 and 63 muM against PARP-1 target, respectively PMID: 27315035
45. The impairment of PARP-dependent DNA damage response (DDR) signaling due to mutations in the FUS nuclear localization sequence induces additional cytoplasmic FUS mislocalization which in turn results in neurodegeneration and FUS aggregate formation in amyotrophic lateral sclerosis. PMID: 29362359
46. Septin4 is a novel essential factor involved in oxidative stress induced vascular endothelial cell injury by interacting with apoptosis-related protein PARP1. PMID: 29366480
47. Data show that the mRNA level of poly(ADP-ribose) polymerase (PARP)-1 was significantly regulated by miR-216b. PMID: 28281524
48. The Gene expression levels of PARP1 was robustly elevated in oligodendrocytes laser captured from BA10 and amygdala white matter of Major Depressive Disorder. PMID: 28034960
49. PARP-1 activates prothrombin gene transcription and that the excessive prothrombin gene transcription induces des-gamma-carboxy prothrombin (DCP) production in DCP-producing hepatocellular carcinoma cells. PMID: 28384634
50. Sodium arsenite induces S-nitrosation on PARP-1 zinc finger DNA binding domain by generating NO through iNOS activation, leading to zinc loss and inhibition of PARP-1 activity, thereby increasing retention of damaged DNA. PMID: 27741521

显示更多

收起更多

HGNC: 270

OMIM: 173870

KEGG: hsa:142

STRING: 9606.ENSP00000355759

UniGene: Hs.177766